Robix Signs LOI With Mexico Consortium to Jointly Market the COV in Mexico

Press Releases  |

LETHBRIDGE, ALBERTA--(March 27, 2015) - Robix Alternative Fuels, Inc. ("Robix" or the "Company") (RZX:CNX) (FRANKFURT:R0X) is pleased to announce that it has formed a Mexican subsidiary, Corris Technologies Mexico S.A. de C.V. (Corris) and through Corris it has entered into a non-binding Letter of Intent (LOI) with Grupo Macomax S.A. de C.V. in Mexico. Grupo Macomax is a Mexican Corporation that offers solutions to environmental emergencies in the whole Mexican territory. Grupo Macomax is a holding company that is part of a multi-million dollar consortium that has been in business for more than 17 years and has developed strong ties with Pemex and the Mexican Federal Government as a reliable service provider.

The purpose of the LOI is to reflect the desire of the parties to agree upon the terms of a commercial transaction, whereby Robix's Clean Ocean Vessel (COV) technology will be introduced to Mexico and utilized for oil spill recovery and remediation in that country. Efforts are currently underway to arrange for shipping the recently manufactured COV to Mexico for reassembly, testing and deployment upon the execution of a definitive agreement.

In addition, Corris has retained the services of local Mexican marketing experts Fidus & Creare to assist with the marketing of the COV in Mexico. For more information on Corris and the COV please visit the newly launched website

About Robix Alternative Fuels

The Corporation is an "industrial products/technology" company, which has developed the Clean Ocean Vessel ("COV"), an oil spill recovery vessel design with the capability to recover oil not only in rough and debris laden sea conditions but more contained environments such as lakes and rivers. Robix has recognized a worldwide market opportunity for effective containment, recovery and disposal equipment, particularly in the oil spill protection industry. The business model is focused on Robix becoming a large-scale provider of services and/or equipment under licensing agreements with other industry participants, wherein Robix will use its COV patented design solution.

No stock exchange or any securities regulatory body has reviewed the contents of this news release.


Contact Information

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor,; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.